Sigma Planning Corp’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $305K | Buy |
3,806
+288
| +8% | +$23.7K | 0.01% | 1045 |
|
|
2025
Q4 | $300K | Sell |
3,518
-53
| -1% | -$4.35K | 0.01% | 1024 |
|
|
2025
Q3 | $278K | Sell |
3,571
-294
| -8% | -$23K | 0.01% | 1058 |
|
|
2025
Q2 | $302K | Sell |
3,865
-190
| -5% | -$14.2K | 0.01% | 985 |
|
|
2025
Q1 | $294K | Buy |
4,055
+191
| +5% | +$13.7K | 0.01% | 954 |
|
|
2024
Q4 | $286K | Sell |
3,864
-268
| -6% | -$18.8K | 0.01% | 947 |
|
|
2024
Q3 | $273K | Sell |
4,132
-1,284
| -24% | -$93.3K | 0.01% | 996 |
|
|
2024
Q2 | $500K | Buy |
5,416
+762
| +16% | +$67.5K | 0.02% | 723 |
|
|
2024
Q1 | $445K | Buy |
+4,654
| New | +$391K | 0.01% | 806 |
|
|
2023
Q4 | – | Sell |
-5,800
| Closed | -$402K | – | 944 |
|
|
2023
Q3 | $402K | Buy |
5,800
+488
| +9% | +$39.2K | 0.02% | 801 |
|
|
2023
Q2 | $501K | Sell |
5,312
-1,740
| -25% | -$151K | 0.02% | 735 |
|
|
2023
Q1 | $583K | Sell |
7,052
-110
| -2% | -$8.65K | 0.02% | 740 |
|
|
2022
Q4 | $534K | Sell |
7,162
-27
| -0.4% | -$2.08K | 0.02% | 741 |
|
|
2022
Q3 | $594K | Buy |
7,189
+310
| +5% | +$29.8K | 0.02% | 671 |
|
|
2022
Q2 | $654K | Sell |
6,879
-8,082
| -54% | -$837K | 0.02% | 638 |
|
|
2022
Q1 | $1.76M | Sell |
14,961
-94
| -0.6% | -$10.5K | 0.05% | 348 |
|
|
2021
Q4 | $1.95M | Sell |
15,055
-3,953
| -21% | -$461K | 0.05% | 330 |
|
|
2021
Q3 | $2.15M | Buy |
19,008
+2,941
| +18% | +$336K | 0.06% | 309 |
|
|
2021
Q2 | $1.66M | Buy |
16,067
+423
| +3% | +$39.9K | 0.05% | 377 |
|
|
2021
Q1 | $1.31M | Buy |
15,644
+745
| +5% | +$63K | 0.04% | 419 |
|
|
2020
Q4 | $1.36M | Sell |
14,899
-519
| -3% | -$43K | 0.05% | 368 |
|
|
2020
Q3 | $1.23M | Buy |
15,418
+992
| +7% | +$77.4K | 0.05% | 346 |
|
|
2020
Q2 | $997K | Buy |
14,426
+152
| +1% | +$10.8K | 0.04% | 394 |
|
|
2020
Q1 | $897K | Sell |
14,274
-1,101
| -7% | -$79.4K | 0.05% | 347 |
|
|
2019
Q4 | $1.2M | Sell |
15,375
-1,848
| -11% | -$144K | 0.05% | 358 |
|
|
2019
Q3 | $1.26M | Buy |
17,223
+3,801
| +28% | +$267K | 0.06% | 321 |
|
|
2019
Q2 | $827K | Buy |
13,422
+2,343
| +21% | +$142K | 0.04% | 392 |
|
|
2019
Q1 | $707K | Buy |
11,079
+5,769
| +109% | +$329K | 0.04% | 402 |
|
|
2018
Q4 | $271K | Sell |
5,310
-150
| -3% | -$7.59K | 0.02% | 643 |
|
|
2018
Q3 | $317K | Buy |
5,460
+105
| +2% | +$5.13K | 0.02% | 661 |
|
|
2018
Q2 | $260K | Buy |
5,355
+120
| +2% | +$5.6K | 0.02% | 711 |
|
|
2018
Q1 | $243K | Sell |
5,235
-432
| -8% | -$18.8K | 0.02% | 695 |
|
|
2017
Q4 | $213K | Buy |
5,667
+42
| +0.7% | +$1.54K | 0.02% | 753 |
|
|
2017
Q3 | $205K | Buy |
5,625
+120
| +2% | +$4.58K | 0.02% | 766 |
|
|
2017
Q2 | $217K | Buy |
+5,505
| New | +$201K | 0.02% | 675 |
|
|
2016
Q4 | – | Sell |
-21,414
| Closed | -$861K | – | 759 |
|
|
2016
Q3 | $861K | Buy |
21,414
+13,587
| +174% | +$512K | 0.1% | 225 |
|
|
2016
Q2 | $260K | Buy |
7,827
+93
| +1% | +$3.18K | 0.03% | 528 |
|
|
2016
Q1 | $227K | Buy |
+7,734
| New | +$213K | 0.03% | 553 |
|
|
2015
Q2 | – | Sell |
-18,714
| Closed | -$444K | – | 726 |
|
|
2015
Q1 | $444K | Buy |
18,714
+6,528
| +54% | +$146K | 0.06% | 379 |
|
|
2014
Q4 | $259K | Buy |
+12,186
| New | +$245K | 0.03% | 556 |
|
Other funds holding EW
VCM
VPM
Sigma Planning Corp's EW Position: Q1 2026 in Review
Sigma Planning Corp increased its Edwards Lifesciences (EW) stake by 8.2% in Q1 2026, buying an estimated $23.7K and bringing the position to 3,806 shares worth $305K. The position accounts for 0.01% of the portfolio, ranked #1045.
Sigma Planning Corp first reported a position in EW in Q4 2014 and has held it in 40 quarters since. The position peaked at $2.15M in Q3 2021. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Sigma Planning Corp held 3,806 shares of Edwards Lifesciences worth $305K as of Q1 2026.
- Sigma Planning Corp bought 288 Edwards Lifesciences shares in Q1 2026, an estimated $23.7K.
- Edwards Lifesciences made up 0.01% of Sigma Planning Corp's portfolio in Q1 2026, its #1045 holding.
- Sigma Planning Corp first reported a position in Edwards Lifesciences in Q4 2014 and has held it in 40 quarters since.
- Sigma Planning Corp's Edwards Lifesciences position peaked at $2.15M in Q3 2021.
- 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Sigma Planning Corp's 13F filing for Q1 2026, filed 4 May 2026.